Project Grant R01AI184778
Award Date
7/12/24
Completion Date
6/30/29
Dollars Obligated
$882K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This $471,159 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the mechanisms by which alpha herpesviruses, such as herpes simplex virus-1 (HSV-1), invade the peripheral nervous system. The 5-year research project, awarded to the University of California, Irvine, aims to investigate how the response of peripheral nerve axons to the cytokine...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $658,273 in funding to the University of Massachusetts Medical School to investigate how the Herpes Simplex Virus 1 (HSV-1) regulates the NLRP1 inflammasome pathway and contributes to antiviral defense in human skin. The goals of this 5-year project are to: 1) determine how the HSV-1 ICP0 protein activates...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $236,292 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Tufts University School of Medicine to capture and characterize the structural complexes of the herpes simplex virus (HSV) glycoproteins critical for viral entry. The project aims to use new methods to isolate and analyze the 3D structures of the GD/GH/GL and GH/GL/GB glycoprotein complexes involved in HSV cell entry, which have been...
This federal Project Grant award of $651,832 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the herpes simplex virus (HSV-1) manipulates the host cell's DNA damage response and proteome to promote viral gene expression and replication. The research team at The Children's Hospital of Philadelphia will use multi-modal proteomics techniques to define how changes to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing a potentially curative gene editing therapy for latent Herpes Simplex Virus Type 2 (HSV-2) infection. The $303,731 award to Caladan Therapeutics, Inc. aims to select and validate a lead meganuclease variant that can specifically target and eliminate HSV-2 from latently infected ganglionic neurons, which...
This $107,948 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to investigate the local and systemic coordination of antiviral immunity by tissue-resident memory CD8 T cells in the skin. The two-year project, running from February 1, 2025 to August 25, 2027, aims to determine whether CD8 tissue-resident memory T cells in the skin can orchestrate an immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,486,800.00 to the Albert Einstein College of Medicine to conduct research on the role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for herpes simplex virus (HSV) vaccine development. The project aims to identify the signaling pathways and structural determinants that...
This Project Grant award, valued at $215,810 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms by which the herpes simplex virus type 1 (HSV-1) degrades host proteins in neurons to enable viral replication and reactivation from latency. The primary awardee, the University of Virginia, will collaborate with the University of Cambridge to: 1)...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the in vivo mechanisms of the innate immune response to HIV-1 infection. The award, totaling $231,752.00, will be provided to the Fred Hutchinson Cancer Center in Seattle, WA from August 1, 2024 through June 30, 2026. The research aims to identify the cellular sources of...
This federal Project Grant award, totaling $131,268, was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research at George Washington University to assess the role of the phosphatases PTPN1 and PTPN2 in controlling the activation and expression of cytotoxic proteins in natural killer (NK) cells. The research aims to enhance the cytolytic activity of NK cells against...